Literature DB >> 28050142

Annual surveillance mammography after early-stage breast cancer and breast cancer mortality.

L F Paszat1, R Sutradhar1, S Gu1, E Rakovitch1.   

Abstract

BACKGROUND: After treatment for early-stage breast cancer (bca), annual surveillance mammography (asm) is recommended based on the assumption that early detection of an invasive ipsilateral breast tumour recurrence or subsequent invasive contralateral primary bca reduces bca mortality.
METHODS: We studied women with unilateral early-stage bca treated by breast-conserving surgery from 1994 to 1997 who subsequently developed an ipsilateral recurrence or contralateral primary more than 24 months after initial diagnosis, without prior regional or distant metastases. Annual surveillance mammography was defined as 2 episodes of bilateral mammography 11-18 months apart during the 2 years preceding the ipsilateral recurrence or contralateral primary. The association between asm and bca death was evaluated using a Cox proportional hazards model.
RESULTS: We identified 669 women who experienced invasive ipsilateral recurrence (n = 455) or a contralateral primary (n = 214) at a median interval of 53 months [interquartile range (iqr): 37-72 months] after initial diagnosis, 64.7% of whom had received asm during the preceding 2 years. The median interval between the 2 bilateral mammograms was 12.3 months (iqr: 11.9-13.0 months), and the median interval between the 2nd mammogram and histopathologic confirmation of ipsilateral recurrence or contralateral primary was 1.5 months (iqr: 0.8-3.9 months). Median followup after ipsilateral recurrence or contralateral primary was 7.76 years (iqr: 3.68-9.81 years). The adjusted hazard ratio for bca death associated with asm was 0.86 (95% confidence limits: 0.63, 1.16).
CONCLUSIONS: Annual surveillance mammography was associated with a modestly lowered hazard ratio for bca death.

Entities:  

Keywords:  Breast cancer; contralateral breast cancer; local recurrence; mortality; propensity score adjustment; proportional hazards regression; surveillance mammography

Year:  2016        PMID: 28050142      PMCID: PMC5176379          DOI: 10.3747/co.23.3399

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  24 in total

1.  A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use.

Authors:  Peter C Austin; Muhammad M Mamdani
Journal:  Stat Med       Date:  2006-06-30       Impact factor: 2.373

2.  Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update).

Authors:  Eva Grunfeld; Sukhbinder Dhesy-Thind; Mark Levine
Journal:  CMAJ       Date:  2005-05-10       Impact factor: 8.262

3.  Digital versus screen-film mammography: impact of mammographic density and hormone therapy on breast cancer detection.

Authors:  Anna M Chiarelli; Maegan V Prummel; Derek Muradali; Rene S Shumak; Vicky Majpruz; Patrick Brown; Hedy Jiang; Susan J Done; Martin J Yaffe
Journal:  Breast Cancer Res Treat       Date:  2015-10-30       Impact factor: 4.872

4.  Long-term surveillance mammography and mortality in older women with a history of early stage invasive breast cancer.

Authors:  Diana S M Buist; Jaclyn L F Bosco; Rebecca A Silliman; Heather Taffet Gold; Terry Field; Marianne Ulcickas Yood; Virginia P Quinn; Marianne Prout; Timothy L Lash
Journal:  Breast Cancer Res Treat       Date:  2013-10-11       Impact factor: 4.872

Review 5.  Mammographic surveillance in women with a personal history of breast cancer: how accurate? How effective?

Authors:  Nehmat Houssami; Stefano Ciatto
Journal:  Breast       Date:  2010-06-12       Impact factor: 4.380

6.  Early detection of second breast cancers improves prognosis in breast cancer survivors.

Authors:  N Houssami; S Ciatto; F Martinelli; R Bonardi; S W Duffy
Journal:  Ann Oncol       Date:  2009-03-17       Impact factor: 32.976

7.  Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis.

Authors:  W L Lu; L Jansen; W J Post; J Bonnema; J C Van de Velde; G H De Bock
Journal:  Breast Cancer Res Treat       Date:  2008-04-18       Impact factor: 4.872

8.  Quality of non-breast cancer health maintenance among elderly breast cancer survivors.

Authors:  Craig C Earle; Harold J Burstein; Eric P Winer; Jane C Weeks
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

Review 9.  Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.

Authors:  James L Khatcheressian; Patricia Hurley; Elissa Bantug; Laura J Esserman; Eva Grunfeld; Francine Halberg; Alexander Hantel; N Lynn Henry; Hyman B Muss; Thomas J Smith; Victor G Vogel; Antonio C Wolff; Mark R Somerfield; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

10.  Adherence to long-term surveillance mammography among women with ductal carcinoma in situ treated with breast-conserving surgery.

Authors:  Larissa Nekhlyudov; Laurel A Habel; Ninah S Achacoso; Inkyung Jung; Reina Haque; Laura C Collins; Stuart J Schnitt; Charles P Quesenberry; Suzanne W Fletcher
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

View more
  2 in total

1.  Mammography use in relation to comorbidities and functional limitations among older breast cancer survivors.

Authors:  Dongyu Zhang; Shailesh Advani; Zhikai Zhu; Le Dang; Louise C Walter; Dejana Braithwaite
Journal:  J Cancer Surviv       Date:  2020-07-28       Impact factor: 4.442

2.  Adherence to the Dutch Breast Cancer Guidelines for Surveillance in Breast Cancer Survivors: Real-World Data from a Pooled Multicenter Analysis.

Authors:  Teresa Draeger; Vinzenz Voelkel; Kay Schreuder; Jeroen Veltman; Anneriet Dassen; Luc Strobbe; Harald J Heijmans; Ron Koelemij; Catharina G M Groothuis-Oudshoorn; Sabine Siesling
Journal:  Oncologist       Date:  2022-10-01       Impact factor: 5.837

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.